Your browser doesn't support javascript.
The Bacterial Mucosal Immunotherapy MV130 Protects Against SARS-CoV-2 Infection and Improves COVID-19 Vaccines Immunogenicity.
Del Fresno, Carlos; García-Arriaza, Juan; Martínez-Cano, Sarai; Heras-Murillo, Ignacio; Jarit-Cabanillas, Aitor; Amores-Iniesta, Joaquín; Brandi, Paola; Dunphy, Gillian; Suay-Corredera, Carmen; Pricolo, Maria Rosaria; Vicente, Natalia; López-Perrote, Andrés; Cabezudo, Sofía; González-Corpas, Ana; Llorca, Oscar; Alegre-Cebollada, Jorge; Garaigorta, Urtzi; Gastaminza, Pablo; Esteban, Mariano; Sancho, David.
  • Del Fresno C; Department of Myocardial Pathophysiology, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
  • García-Arriaza J; Department of Infectious Diseases and Immunity, Instituto de Investigación Biomédica del Hospital Universitario la Paz (IdiPAZ), Madrid, Spain.
  • Martínez-Cano S; Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología (CNB), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.
  • Heras-Murillo I; Department of Myocardial Pathophysiology, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
  • Jarit-Cabanillas A; R&D Department, Inmunotek S.L., Alcalá de Henares, Spain.
  • Amores-Iniesta J; Department of Myocardial Pathophysiology, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
  • Brandi P; Department of Myocardial Pathophysiology, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
  • Dunphy G; Department of Myocardial Pathophysiology, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
  • Suay-Corredera C; Department of Myocardial Pathophysiology, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
  • Pricolo MR; Department of Myocardial Pathophysiology, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
  • Vicente N; Department of Myocardial Pathophysiology, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
  • López-Perrote A; Department of Myocardial Pathophysiology, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
  • Cabezudo S; Department of Myocardial Pathophysiology, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
  • González-Corpas A; Structural Biology Department, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain.
  • Llorca O; Structural Biology Department, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain.
  • Alegre-Cebollada J; Structural Biology Department, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain.
  • Garaigorta U; Structural Biology Department, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain.
  • Gastaminza P; Department of Myocardial Pathophysiology, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
  • Esteban M; Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología (CNB), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.
  • Sancho D; Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología (CNB), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.
Front Immunol ; 12: 748103, 2021.
Article in English | MEDLINE | ID: covidwho-1555317
ABSTRACT
COVID-19-specific vaccines are efficient prophylactic weapons against SARS-CoV-2 virus. However, boosting innate responses may represent an innovative way to immediately fight future emerging viral infections or boost vaccines. MV130 is a mucosal immunotherapy, based on a mixture of whole heat-inactivated bacteria, that has shown clinical efficacy against recurrent viral respiratory infections. Herein, we show that the prophylactic intranasal administration of this immunotherapy confers heterologous protection against SARS-CoV-2 infection in susceptible K18-hACE2 mice. Furthermore, in C57BL/6 mice, prophylactic administration of MV130 improves the immunogenicity of two different COVID-19 vaccine formulations targeting the SARS-CoV-2 spike (S) protein, inoculated either intramuscularly or intranasally. Independently of the vaccine candidate and vaccination route used, intranasal prophylaxis with MV130 boosted S-specific responses, including CD8+-T cell activation and the production of S-specific mucosal IgA antibodies. Therefore, the bacterial mucosal immunotherapy MV130 protects against SARS-CoV-2 infection and improves COVID-19 vaccines immunogenicity.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Bacteria / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 Topics: Vaccines Limits: Animals Language: English Journal: Front Immunol Year: 2021 Document Type: Article Affiliation country: Fimmu.2021.748103

Full text: Available Collection: International databases Database: MEDLINE Main subject: Bacteria / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 Topics: Vaccines Limits: Animals Language: English Journal: Front Immunol Year: 2021 Document Type: Article Affiliation country: Fimmu.2021.748103